Eli Lilly and Company (BVMF:LILY34)

Market Cap	3.81T
Revenue (ttm)	280.96B
Net Income (ttm)	63.68B
Shares Out	n/a
EPS (ttm)	70.46
PE Ratio	59.87
Forward PE	30.80
Dividend	0.73 (0.51%)
Ex-Dividend Date	May 15, 2025

Volume	15,851
Average Volume	17,458
Open	140.98
Previous Close	141.40
Day's Range	140.20 - 144.50
52-Week Range	132.28 - 181.98
Beta	0.39
RSI	46.69
Earnings Date	Aug 7, 2025

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: LILY34

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD